Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | ENPP3 | O14638 | 5/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278182 | 0.79 | ENPP3 (0.69) | ENPP3ENPP1HSD17B1HSD17B2SMO | |
| Benzene SCHEMBL16781371 | 0.79 | ENPP3 (0.69) | ENPP3ENPP1HSD17B1HSD17B2SMO | |
| SCHEMBL31606598 | 0.77 | ENPP3 (0.67) | ENPP3ENPP1HSD17B1HSD17B2SMO | |
| SCHEMBL3271684 | 0.77 | ENPP3 (0.72) | ENPP3ENPP1HSD17B1HSD17B2SMO | |
| SCHEMBL11566150 | 0.77 | ENPP3 (0.72) | ENPP3ENPP1HSD17B1HSD17B2SMO | |
| SCHEMBL28370241 | 0.77 | SMN1; SMN2 (0.51) | ENPP3ENPP1HSD17B1HSD17B2HSP90AA1 | |
| SCHEMBL301469 | 0.77 | HPGDS (0.71) | HPGDSLTA4HPIN1RAB9AHPGD | |
| SCHEMBL2198916 | 0.76 | ENPP3 (0.65) | ENPP3ENPP1HSD17B1HSD17B2ADORA2A | |
| SCHEMBL5664564 | 0.76 | ENPP3 (0.75) | ENPP3ENPP1HSD17B1HSD17B2SMO | |
| SCHEMBL28753616 | 0.75 | HPGDS (0.69) | HPGDSLTA4HPIN1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076033-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | ROBL JEFFREY A | 2009-03-19 | — | — | US | claimed |
| EP-1121129-B1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | claimed |
| US-7390824-B1 | Method for treating diabetes employing an aP2 inhibitor and combination | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | claimed |
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-11-18 | — | — | US | claimed |
| EP-1121129-A4 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL MYERS SQUIBB CO (US) | 2002-10-16 | — | — | EP | claimed |
| EP-1113801-A4 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL MYERS SQUIBB CO (US) | 2002-10-02 | — | — | EP | claimed |
| JP-2002524517-A | — | — | 2002-08-06 | — | — | JP | claimed |
| JP-2002524518-A | — | — | 2002-08-06 | — | — | JP | claimed |
| US-20020035064-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-21 | — | — | US | claimed |
| EP-1121129-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-08 | — | — | EP | claimed |
| EP-1113801-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-07-11 | — | — | EP | claimed |
| WO-2000015230-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| WO-2000015229-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| US-20090076033-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | ROBL JEFFREY A | 2009-03-19 | — | — | US | disclosed |
| EP-1121129-B1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7390824-B1 | Method for treating diabetes employing an aP2 inhibitor and combination | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
| US-5292631-A | Radiographic elements with improved covering power | EASTMAN KODAK COMPANY (US) | 1994-03-08 | — | — | US | disclosed |
| EP-0575262-A2 | Radiographic elements with improved covering power | EASTMAN KODAK COMPANY (US) | 1993-12-22 | — | — | EP | disclosed |
| EP-0574331-A2 | Tone control of photographic images | EASTMAN KODAK COMPANY (US) | 1993-12-15 | — | — | EP | disclosed |
| EP-0573373-A2 | Tone control of photographic silver images | EASTMAN KODAK COMPANY (US) | 1993-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035064-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, AP2A2 | HPGDS 561/4885ENPP3 639/4885ENPP1 529/4885 |
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, AP2A2 | HPGDS 561/4885ENPP3 639/4885ENPP1 529/4885 |
| US-20090076033-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, HMGCR | HPGDS 365/4885ENPP3 609/4885ENPP1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.